[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bayer A G Ord (BAYZF)

Bayer A G Ord (BAYZF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 20.57
  • Price/Book 5.23
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.9400 +6.97%
on 06/02/26
45.4100 -8.27%
on 05/20/26
-3.4650 (-7.68%)
since 05/12/26
3-Month
38.9400 +6.97%
on 06/02/26
48.9100 -14.83%
on 04/17/26
-3.5300 (-7.81%)
since 03/12/26
52-Week
29.1600 +42.85%
on 08/06/25
58.3276 -28.58%
on 02/17/26
+9.4000 (+29.14%)
since 06/12/25

Most Recent Stories

More News
Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business

Bayer today announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer’s Pharmaceuticals Division, effective August 1, 2026. In his new capacity, he will report...

BAYRY : 10.4400 (+0.38%)
BAYZF : 41.8400 (+1.16%)
BAYN : 0.0100 (unch)
Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth

Bayer today announced leadership changes within its Consumer Health division to accelerate growth, strengthen commercial execution, and further enhance speed of decision making. These changes reflect the...

BAYRY : 10.4400 (+0.38%)
BAYZF : 41.8400 (+1.16%)
BAYN : 0.0100 (unch)
Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease

Investigational results from FIND-CKD provide full efficacy and safety data and is the fifth consecutive Phase III clinical trial where KERENDIA met its primary endpoint—adding to a clinical trial program...

BAYRY : 10.4400 (+0.38%)
BAYZF : 41.8400 (+1.16%)
BAYN : 0.0100 (unch)
Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Presentations also include the INFINITY pooled analysis of KERENDIA ® (finerenone) across diabetic and non-diabetic chronic kidney disease.

BAYRY : 10.4400 (+0.38%)
BAYZF : 41.8400 (+1.16%)
BAYN : 0.0100 (unch)
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA ® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD)...

BAYRY : 10.4400 (+0.38%)
BAYZF : 41.8400 (+1.16%)
BAYN : 0.0100 (unch)
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio

Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA ® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant...

BAYRY : 10.4400 (+0.38%)
BAYZF : 41.8400 (+1.16%)
BAYN : 0.0100 (unch)
Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease

If approved for this investigational new use, KERENDIA ® (finerenone), a non-steroidal mineralocorticoid antagonist (MRA), would be the first MRA indicated for adults with type 1 diabetes...

BAYRY : 10.4400 (+0.38%)
BAYZF : 41.8400 (+1.16%)
BAYN : 0.0100 (unch)
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

KEY FACTS: Regulatory submission is based on positive results from the Phase III OCEANIC-STROKE study OCEANIC-STROKE met the primary efficacy outcome...

BAYRY : 10.4400 (+0.38%)
BAYZF : 41.8400 (+1.16%)
BAYN : 0.0100 (unch)
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer

Regulatory submission for first-line use of HYRNUO is based on results from the ongoing Phase I/II SOHO-01 trial evaluating the efficacy and safety in patients with advanced HER2 -mutated...

BAYRY : 10.4400 (+0.38%)
BAYZF : 41.8400 (+1.16%)
BAYN : 0.0100 (unch)
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer

Primary results from the Phase II ARASEC trial show that NUBEQA ® (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant improvement in progression-free...

BAYRY : 10.4400 (+0.38%)
BAYZF : 41.8400 (+1.16%)
BAYN : 0.0100 (unch)

Business Summary

Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third-largest in the world. HealthCare subgroup...

See More

Key Turning Points

3rd Resistance Point 41.3600
2nd Resistance Point 41.3600
1st Resistance Point 41.3600
Last Price 41.8400
1st Support Level 41.3600
2nd Support Level 41.3600
3rd Support Level 41.3600

See More

52-Week High 58.3276
Fibonacci 61.8% 47.1856
Fibonacci 50% 43.7438
Last Price 41.8400
Fibonacci 38.2% 40.3020
52-Week Low 29.1600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.